Literature DB >> 7740458

Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria.

H de Ronde1, R M Bertina.   

Abstract

The APC-resistance test consists of two APTT's, one in the presence and one in the absence of a fixed amount of Activated Protein C (APC), and is a simple and reliable method to detect a reduced sensitivity to the anticoagulant action of APC (APC-resistance). At a fixed concentration of APC the prolongation of the APTT is dependent on the activator, the CaCl2 concentration, the citrate concentration in the sample, and on sample handling. The effect of sample handling can be reduced by calculating the APC-Sensitivity Ratio (APC-SR). The actual prolongation of the APTT is also influenced by low protein S levels (reduction of APC-SR) and by reduced levels of factors V, VIII and IX (increase of APC-SR). The APC-SR is most dramatically effected by reduced levels of factors II and X, which result often in "unmeasurable" APC-SR's in plasmas of patients on oral anticoagulant treatment. So at present no reliable APC-SR's can be measured in these patients. Patients treated with heparin can be tested after treatment of their plasma with Hepzym. The inter- and intra-assay variation in the APC-SR is 4% and 2%, respectively, when using the same batches of activator and APC. The variation which is introduced in the APC-SR by use of different batches of activator or APC, or by the use of different APC or CaCl2 concentrations, can effectively be avoided by expressing the result of the test in normalized-APC-SR (n-APC-SR).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7740458

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy.

Authors:  H Shu; M Wramsby; M Bokarewa; M Blombäck; K Bremme
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

2.  Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.

Authors:  Gianluca Gessoni; Sara Valverde; Letizia Valle; Pierpaolo Caruso; Francesca Gessoni; Roberto Valle
Journal:  Blood Transfus       Date:  2017-03-07       Impact factor: 3.443

3.  Evaluation of role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative DVT patients: a study in India.

Authors:  Amit Sharma; Kanwaljeet Singh; Arijit Biswas; Ravi Ranjan; Kamal Kishor; Ravi Kumar; Hareram Pandey; Vineet Kumar Kamal; Renu Saxena
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

4.  Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it.

Authors:  A Girolami; P Simioni; L Scarano; B Girolami; P Zerbinati
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

Review 5.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

6.  Lifetime Risk of Venous Thromboembolism in Two Cohort Studies.

Authors:  Elizabeth J Bell; Pamela L Lutsey; Saonli Basu; Mary Cushman; Susan R Heckbert; Donald M Lloyd-Jones; Aaron R Folsom
Journal:  Am J Med       Date:  2015-11-18       Impact factor: 4.965

7.  Lack of association of soluble endothelial protein C receptor and PROCR 6936A/G polymorphism with the risk of venous thromboembolism in a prospective study.

Authors:  Kazumasa Yamagishi; Mary Cushman; Susan R Heckbert; Michael Y Tsai; Aaron R Folsom
Journal:  Br J Haematol       Date:  2009-02-17       Impact factor: 6.998

8.  High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

Authors:  J H Griffin; K Kojima; C L Banka; L K Curtiss; J A Fernández
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

9.  Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen.

Authors:  Luuk J J Scheres; Nienke L D Selier; Nienke M Nota; Jeske J K van Diemen; Suzanne C Cannegieter; Martin den Heijer
Journal:  J Thromb Haemost       Date:  2021-02-22       Impact factor: 5.824

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.